[go: up one dir, main page]

MX2018001145A - Métodos para la preparación de ácidos biliares y derivados de los mismos. - Google Patents

Métodos para la preparación de ácidos biliares y derivados de los mismos.

Info

Publication number
MX2018001145A
MX2018001145A MX2018001145A MX2018001145A MX2018001145A MX 2018001145 A MX2018001145 A MX 2018001145A MX 2018001145 A MX2018001145 A MX 2018001145A MX 2018001145 A MX2018001145 A MX 2018001145A MX 2018001145 A MX2018001145 A MX 2018001145A
Authority
MX
Mexico
Prior art keywords
derivatives
preparation
methods
bile acids
solvate
Prior art date
Application number
MX2018001145A
Other languages
English (en)
Inventor
Pellicciari Roberto
Gioiello Antimo
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018001145A publication Critical patent/MX2018001145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/0035—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a un método de preparación de compuestos de fórmula (I): VER FORMULA (I), O una sal, solvato o conjugado con aminoácido farmacéuticamente aceptable de los mismos, R1 es H, a-OH, ß-OH o un grupo de oxo.
MX2018001145A 2015-07-30 2016-07-22 Métodos para la preparación de ácidos biliares y derivados de los mismos. MX2018001145A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562198733P 2015-07-30 2015-07-30
PCT/US2016/043611 WO2017019524A1 (en) 2015-07-30 2016-07-22 Methods for preparation of bile acids and derivatives thereof

Publications (1)

Publication Number Publication Date
MX2018001145A true MX2018001145A (es) 2018-06-15

Family

ID=57885146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001145A MX2018001145A (es) 2015-07-30 2016-07-22 Métodos para la preparación de ácidos biliares y derivados de los mismos.

Country Status (15)

Country Link
US (1) US10414791B2 (es)
EP (1) EP3328817A4 (es)
JP (1) JP6830096B2 (es)
KR (1) KR20180030204A (es)
CN (1) CN108025994A (es)
AR (1) AR105555A1 (es)
AU (1) AU2016297821B2 (es)
BR (1) BR112018001869A2 (es)
CA (1) CA2993540A1 (es)
IL (1) IL256971A (es)
MA (1) MA43066A (es)
MX (1) MX2018001145A (es)
NZ (1) NZ739219A (es)
TW (1) TW201710280A (es)
WO (1) WO2017019524A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305799A3 (en) * 2016-10-07 2018-06-20 Lupin Limited Salts of obeticholic acid
WO2018194426A1 (ko) * 2017-04-20 2018-10-25 대웅바이오 주식회사 연속흐름반응을 이용한 담즙산 유도체의 제조 방법
CN107200763B (zh) * 2017-06-01 2019-05-03 江苏佳尔科药业集团有限公司 一种以鹅去氧胆酸为原料合成石胆酸的方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法
CA3190433A1 (en) * 2020-08-21 2022-02-24 Sandhill One, Llc Methods of making cholic acid derivatives and starting materials therefor
CN112220792A (zh) * 2020-09-30 2021-01-15 浙江大学 石胆酸用于制备缓解肝纤维化的药物中的应用
WO2023081658A2 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived tudca
WO2023081657A2 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived udca
CN114276397A (zh) * 2021-12-28 2022-04-05 湖北武当安泰药业有限公司 醋酸去氢表雄酮的制备方法
WO2023187398A1 (en) 2022-03-31 2023-10-05 NZP UK Limited 7-ketolithocholic acid for use in the treatment of gut dysbiosis and as a prebiotic

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360470A (en) * 1980-10-22 1982-11-23 Hoffmann-La Roche Inc. Process and intermediates for the synthesis of Vitamin D3 metabolites and chenodeoxycholic acid
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP2083621A4 (en) * 2006-11-20 2010-03-24 Satori Pharmaceuticals Inc MODULATORS OF AMYLOID BETA PRODUCTION
US20080318870A1 (en) * 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
EP2407475B1 (en) * 2007-06-19 2015-08-12 Kythera Biopharmaceuticals, Inc. synthetic bile acid preparation
WO2012047495A2 (en) * 2010-09-27 2012-04-12 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
AU2012304412A1 (en) * 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN102746356B (zh) * 2012-07-17 2014-03-05 湖北芳通药业股份有限公司 均相法生产醋酸去氢表雄酮的工艺方法
MX2015012437A (es) 2013-03-13 2016-04-15 Sage Therapeutics Inc Esteroides neuroactivos, composiciones, y usos de los mismos.
CN103145784B (zh) 2013-03-25 2015-03-11 浙江仙琚制药股份有限公司 醋酸去氢表雄酮的制备方法
CN104045676A (zh) * 2013-12-13 2014-09-17 成都丽璟科技有限公司 一种生产双烯醇酮醋酸酯的方法

Also Published As

Publication number Publication date
CN108025994A (zh) 2018-05-11
AU2016297821B2 (en) 2020-03-12
US20190010184A1 (en) 2019-01-10
KR20180030204A (ko) 2018-03-21
EP3328817A4 (en) 2019-04-03
AR105555A1 (es) 2017-10-18
BR112018001869A2 (pt) 2018-09-18
NZ739219A (en) 2019-03-29
JP6830096B2 (ja) 2021-02-17
EP3328817A1 (en) 2018-06-06
CA2993540A1 (en) 2017-02-02
AU2016297821A1 (en) 2018-02-15
WO2017019524A1 (en) 2017-02-02
MA43066A (fr) 2018-06-06
US10414791B2 (en) 2019-09-17
JP2018523654A (ja) 2018-08-23
TW201710280A (zh) 2017-03-16
IL256971A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
MX2018001145A (es) Métodos para la preparación de ácidos biliares y derivados de los mismos.
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
MX2020005956A (es) Sales organicas de acido sulfonico de esteres de aminoacidos y proceso para su preparacion.
PH12018500777A1 (en) Farnesoid x receptor modulators
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX2018005520A (es) Metodos para preparacion de acido obeticolico y derivados de los mismos.
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
MX2019011844A (es) Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MY191352A (en) Aldosterone synthase inhibitors
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
MX2018012777A (es) Métodos para preparación de ácido obeticólico y derivados de los mismos.
PH12016501704B1 (en) Method for producing 2-acyliminopyridine derivative
MX2018015990A (es) Compuestos terapeuticos.
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
WO2016029216A3 (en) Method for producing amidine derivatives
WO2016038622A3 (en) Improved process for the preparation of [[2(s)-[[4(r)-(3-hydroxyphenyl)-3(r),4-dimethyl-1-piperidinyl]methyl]-1 -oxo-3-phenylpropyl]amino]acetic acid dihydrate
PH12022550529A1 (en) Magl inhibitor, preparation method and use thereof
HK1231073A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MX2018001414A (es) Sal del ester metilico dihidrofenilglicina.